A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma.

Citation metadata

Publisher: BioMed Central Ltd.
Document Type: Article
Length: 8,806 words
Lexile Measure: 1470L

Document controls

Main content

Abstract :

Neuroblastoma is the most common extra-cranial solid tumor in children, representing approximately 8% of all malignant childhood tumors and 15% of pediatric cancer-related deaths. Recent sequencing and transcriptomics studies have demonstrated the RAS-MAPK pathway's contribution to the development and progression of neuroblastoma. This review compiles up-to-date evidence of this pathway's involvement in neuroblastoma. We discuss the RAS-MAPK pathway's general functioning, the clinical implications of its deregulation in neuroblastoma, and current promising therapeutics targeting proteins involved in signaling. Keywords: Neuroblastoma, RAS-MAPK, ALK, RAS, MEK1/2, ERK1/2, RASopathie, Inhibitors

Source Citation

Source Citation   

Gale Document Number: GALE|A665424985